Cingulateの空売り状況は、投資家がCingulateの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Cingulate (NASDAQ:CING) 株価情報, 空売り情報

Cingulate

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Cingulate Inc

COINSILIUM GROUP LTD ORD by Coinsilium Group Ltd.

Coinsilium Group Ltd

Central Japan Railway (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CJPRY#OTC">CJPRY</a>) reported quarterly earnings of $0.10 per share. This is a 11.11 percent increase over earnings of $0.09 per share from the same period last year. The company reported $3.24 billion in sales this quarter. This is a 5.22 percent increase over sales of $3.08 billion the same period last year.

Earnings

News

CJPRY

Central Japan Railway Q3 EPS $0.10 Up From $0.09 YoY, Sales $3.24B Up From $3.08B YoY

Loop Capital analyst Rick Paterson downgrades Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) from Hold to Sell and lowers the price target from $265 to $200.

Downgrades

Price Target

Analyst Ratings

Loop Capital Downgrades Union Pacific to Sell, Lowers Price Target to $200

Shares of Michael Saylor&#8216;s MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) declined over 5% in premarket hours on Monday after Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/25/02/43425613/bitcoin-crashes-below-92000-ethereum-dogecoin-slump-as-trumps-tariff-war-spooks-investors-analyst">prices fell</a>.
What Happened: Bitcoin, along with other cryptocurrencies tumbled after President Donald Trump&#8216;s tariff war pounded the capital markets.
After falling on Sunday below $92,000 for the first time since Jan. 13, BTC recovered to 95,152.35, on Monday, still down 4.2%, during the publication of this article.
Bitcoin&#8217;s levered play MicroStrategy was down 5.81% to $315.35 per share, following the former&#8217;s decline.
This also followed Friday&#8217;s announcement of 8% 7.3 million preferred shares with a strike price of $80.00 apiece, with settlement expected on Feb. 5.
The company acquired an additional 10,107 Bitcoin this week, extending its buying spree to twelve consecutive weeks and bringing its total holdings to 471,107 BTC.
The cryptocurrency market, along with equity futures struggled as Trump <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43398182/trumps-25-tariffs-could-slaughter-canada-mexico-economies-hit-us-auto-industry-analysts-warn">imposed tariffs</a> on major trade partners, a decision that could disrupt crucial supply chains throughout North America and affect economies. 
See Also: <a href="https://www.benzinga.com/25/02/43428231/as-dollar-strengthens-after-trumps-tariff-imposition-this-hedge-fund-manager-says-usd-devaluation-is-inevitable-heres-why">Trump Tariffs Strengthen Dollar, But Hedge Fund CEO Sees Impending Decline</a>
Why It Matters: Saylor was featured on the Forbes front cover last week titled &#8220;The Bitcoin Alchemist.&#8221; Ed Yardeni and Eric Wallerstein in their QuickTakes note mentioned that &#8220;the magazine has also featured a few rising stars who subsequently crashed and burned.&#8221;
After BTC&#8217;s Sunday crash, the note stated, &#8220;In any event: We have been warned.&#8221;
The exchange-traded fund, Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) tracking Nasdaq 100 declined 1.60% to $513.92. MSTR underperformed the gauge by falling 5.08% to $317.78 per share.
Mizuho recently initiated coverage on the company with an ‘outperform' rating and a $515 price target, describing it as a "Lever for the Believer" in Bitcoin.
The average price target among 13 <a href="https://www.benzinga.com/quote/MSTR/analyst-ratings">analysts tracked by Benzinga</a> is $454.54 with a ‘buy' rating. The estimates range from $690 to $140 apiece. Recent ratings from Mizuho, Benchmark, and Benchmark suggest a $605 target, implying a potential upside of 91.85%.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/MSTR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="385" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03055114/MSTR-anr-new-new-1024x385.png" alt="" class="wp-image-762251" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03055114/MSTR-anr-new-new-1024x385.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03055114/MSTR-anr-new-new-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03055114/MSTR-anr-new-new-768x289.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03055114/MSTR-anr-new-new.png 1060w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43426284/palantir-technologies-pre-earnings-plunge-tariff-impact-or-investor-jitters-heres-what-technical-analysis-suggests">Palantir Technologies Plunges Overnight On Robinhood: Trump Tariff Impact Or Investor Jitters? </a></li>
</ul>
Image Via Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Movers & Shakers

Forex

Economics

Markets

Movers

Trading Ideas

ETFs

General

$BTC

MSTR

Michael Saylor's MicroStrategy Slides Over 5% In Monday Premarket As Bitcoin Takes Tariff Hit Amid Lower Futures

Loop Capital analyst Rick Paterson downgrades FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from Buy to Hold and lowers the price target from $365 to $283.

Loop Capital Downgrades FedEx to Hold, Lowers Price Target to $283

Each of these operations have been operated by an Ensign-affiliated company under two third-party leases with purchase options since 2019.&nbsp;
<ul>
<li>Beacon Harbor Healthcare &amp; Rehabilitation, a 190-bed skilled nursing facility located in Rockwall, Texas;</li>
<li>Pleasant Manor Healthcare &amp; Rehabilitation, a 126-bed skilled nursing facility located in Waxahachie, Texas;</li>
<li>Rowlett Health &amp; Rehabilitation Center, a 150-bed skilled nursing facility located in Rowlett, Texas; and</li>
<li>Crestwood Health &amp; Rehabilitation Center, a healthcare campus with 112 skilled nursing beds and 36 assisted living units located in Wills Point, Texas.</li>
</ul>

ENSG

Ensign Group Says Its Captive Real Estate Company Exercised Purchase Option To Acquire Real Estate Of Certain Skilled Nursing Facilities And Healthcare Campus; No Terms Disclosed

Johnson Outdoors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JOUT#NASDAQ">JOUT</a>) reported quarterly losses of $(1.49) per share which missed the analyst consensus estimate of $(1.30) by 14.62 percent. This is a 492.11 percent decrease over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $107.65 million which beat the analyst consensus estimate of $104.73 million by 2.79 percent. This is a 22.36 percent decrease over sales of $138.64 million the same period last year.

Earnings Beats

Earnings Misses

JOUT

Johnson Outdoors Q1 EPS $(1.49) Misses $(1.30) Estimate, Sales $107.65M Beat $104.73M Estimate

Jefferies analyst Suneet Kamath downgrades Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) from Buy to Hold and announces $64 price target.

Brighthouse Financial, Inc. - Common Stock

Jefferies Downgrades Brighthouse Finl to Hold, Announces $64 Price Target

Futures

Pre-Market Outlook

AMZN

FTNT

GOOG

GOOGL

NXPI

PLTR

SMCI

TBNK

US Stocks Likely To Open Lower As Trump Imposes Tariffs On China, Canada, And Mexico: Expert Notes Feb Worst Month In Post-Election Years

East Japan Railway (OTC:<a class="ticker" href="https://www.benzinga.com/stock/EJPRY#OTC">EJPRY</a>) reported quarterly earnings of $0.07 per share. This is a 65 percent decrease over earnings of $0.20 per share from the same period last year. The company reported $4.80 billion in sales this quarter. This is a 1.12 percent increase over sales of $4.75 billion the same period last year.

EJPRY

East Japan Railway Q3 EPS $0.07 Down From $0.20 YoY, Sales $4.80B Up From $4.75B YoY

Jefferies analyst Surinder Thind downgrades Sapiens Intl Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) from Buy to Hold and lowers the price target from $36 to $28.

SPNS

Jefferies Downgrades Sapiens Intl Corp to Hold, Lowers Price Target to $28

Jefferies analyst Surinder Thind upgrades SS&amp;C Techs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) from Hold to Buy and raises the price target from $70 to $94.

Upgrades

SSNC

Jefferies Upgrades SS&C Techs Hldgs to Buy, Raises Price Target to $94

The Q3 earnings report for Kyocera (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KYOCY#OTC">KYOCY</a>) was released on Monday, February 3, 2025 at 02:00 AM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Kyocera missed estimated earnings by -162.0%, reporting an EPS of $-0.08 versus an estimate of $0.13.
Revenue was down $194.00 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
The company missed on EPS by $0.08 in the last quarter, resulting in a 4.0% drop share price change the following day.

To track all earnings releases for Kyocera <a href="https://www.benzinga.com/quote/KYOCY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KYOCY

Kyocera Q3 Earnings Assessment

Kyocera (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KYOCY#OTC">KYOCY</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $0.13 by 161.54 percent. This is a 150 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $3.24 billion which missed the analyst consensus estimate of $3.28 billion by 1.22 percent. This is a 5.65 percent decrease over sales of $3.43 billion the same period last year.

Kyocera Q3 EPS $(0.08) Misses $0.13 Estimate, Sales $3.24B Miss $3.28B Estimate

Telsey Advisory Group analyst Dana Telsey maintains Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) with a Market Perform and maintains $11 price target.

PTON

Telsey Advisory Group Maintains Market Perform on Peloton Interactive, Maintains $11 Price Target

U.S. stocks settled lower on Friday, with the Dow Jones index falling more than 300 points during the session.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Trevor Walsh
<ul>
<li>Analyst Firm: JMP Securities</li>
<li>Ratings Accuracy: 90%</li>
<li>Latest Rating: Maintained a Market Outperform rating on Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) and raised the price target from $4.5 to $6.5 on Jan. 30. This analyst sees around 11% upside in the stock.</li>
<li>Recent News: On Jan. 29, Planet signed a $230 million commercial agreement for Pelican Satellites.</li>
</ul>
Analyst: Zachary Fadem
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Equal-Weight rating on Brinker International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) and increased the price target from $145 to $175 on Jan. 30. This analyst sees a 3% decline in the stock.</li>
<li>Recent News: On Jan. 29, Brinker International reported better-than-expected second-quarter results.</li>
</ul>
Analyst: Alexander Paris 
<ul>
<li>Analyst Firm: Barrington Research</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Outperform rating on Adtalem Global Education Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NYSE">ATGE</a>) and increased price target from $115 to $120 on Jan. 31. This analyst sees around 12% upside in the stock.</li>
<li>Recent News: On Jan. 30, Adtalem Global Education reported better-than-expected second-quarter financial results and raised its FY25 guidance.</li>
</ul>
Analyst: Rob Owens
<ul>
<li>Analyst Firm: Piper Sandler</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Overweight rating on Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) and raised the price target from $310 to $365 on Jan. 31. This analyst sees around 21% surge in the stock.</li>
<li>Recent News: On Jan. 30, Atlassian reported better-than-expected second-quarter financial results.</li>
</ul>
Analyst: Andres Sheppard
<ul>
<li>Analyst Firm: Cantor Fitzgerald</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained a Neutral rating on Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and boosted the price target from $365 to $425 on Jan. 30. This analyst sees more than 8% upside in the stock.</li>
<li>Recent News: Tesla has started production of its refreshed Model Y across its four factories around the globe including its gigafactory in Texas, the company said in a post on X, formerly Twitter.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Adtalem Global Education Inc. Common Stock

ATGE

TEAM

TSLA

This Analyst With 85% Accuracy Rate Sees More Than 8% Upside In Tesla - Here Are 5 Stock Picks For January From Wall Street's Most Accurate Analysts

We live in a world where facts dissolve into fiction faster than ever. A new plague of deception—fueled not by biology but by algorithms—is spreading globally. Call it the "infodemic," a storm of AI-generated lies, hyper-realistic deepfakes, and synthetic documents, many originating from Chinese tech labs. As those AI tools become increasingly sophisticated in deception, they can corrode trust in more than one way, posing risks to democracy, art, our finances and even love. With elections in over 50 nations looming by 2025, the stakes are existential.
Open-source AI's dark side
Currently, platforms like Midjourney and <a href="https://www.nytimes.com/2024/05/07/technology/openai-deepfake-detector.html">OpenAI's tools </a>have put safeguards in place to prevent misuse, ensuring that content like deepfakes stay out of circulation online as much as possible. However, open-source models can be fine-tuned and weaponized by those with bad intent, empowering scammers to spread disinformation, deepfakes and fraud.&nbsp;
When AI steals the spotlight
The cases of AI scams are probably the most publicized in the entertainment industry. Hollywood in particular now battles synthetic impostors on a regular basis. Public figures must contend with the potential for their likeness to be ripped off for someone else's gain, with deepfakes infiltrating platforms like X on a daily basis, whether it's to offer fake brand endorsements or to generate scandals. This ease of creation, coupled with the vast reach of social media platforms, creates a potent combination for disseminating misinformation and scams.
But not everyone sees this as a loss. Take Grimes, who leases her voice to AI clones for royalties—a "deepfake-as-a-service" model. This begs a grim question: Do artists have to auction their identities to stay relevant?&nbsp;
<h3 class="wp-block-heading">Algorithmic love lies</h3>
Famous artists aside, none of us are safe, particularly when it comes to finding real love. Forget poorly photoshopped profiles—today's catfishing involves AI-generated personas so convincing they mimic celebrities.
With Chinese platforms like DeepSeek, with reasoning capabilities equivalent to ChatGPT, and open source generators like Flux giving users an ability to generate deepfakes with remarkable accuracy, it becomes increasingly challenging for even the most digitally savvy individuals to see through a lie.&nbsp;
According to the FBI, last year 19,000 Americans fell victim to romance scams, losing $1.3 billion. Solutions like watermarking AI content exist, but without global enforcement, fraudsters thrive in the gaps.
How many more Brad Pitt deepfake scams do we need to live through before we do something about it? Platforms <a href="https://venturebeat.com/games/ai-or-not-raises-5m-to-stop-ai-fraud-deepfakes-and-misinformation/">detecting AI</a> across videos, images and texts already help millions of people verify AI generated content, helping them save their money, and even marriages in this case.&nbsp;
<h3 class="wp-block-heading">Beijing's "document mills"</h3>
Another area requiring fast innovation in the realm of fraud detection is KYC scams. Open-source AI models, fine-tuned well, produce fake passports and contracts indistinguishable from real ones. These tools slip past banks' KYC checks, forcing financial institutions into an expensive arms race. Biometric-based fraud has gone up 40% in 2024 and is showing no signs of slowing down. HSBC now uses AI "detectives" to hunt forged documents—a Band-Aid on a bullet wound.
We need to start a discussion about how banks can create an actual filter protecting their customers from falling prey to the next KYC scam.&nbsp;
<h3 class="wp-block-heading">Synthetic news and political manipulation</h3>
Finally, even platforms that used to signify public trust are not safe anymore. Last year, AI impersonated the BBC, publishing fabricated stories about politicians. The fallout wasn't just embarrassment—it was a warning. In 2025, as billions vote globally, such scams need to be taken more seriously. The attack won't come from hackers, but from code written in Shenzhen or Shanghai.
This is already a reality in China. For example, a disinformation <a href="https://jamestown.org/program/deepfakes-with-chinese-characteristics-prc-influence-operations-in-2024/">campaign </a>aimed at DPP presidential candidate Lai Ching-Te was flooded with deepfake content. Manipulated videos, using synthesized versions of Lai&#8217;s voice, misleadingly showed him endorsing a coalition between the KMT and TPP, and inaccurately depicted him discussing DPP scandals. While sharing content across platforms is a staple in influence operations, Beijing&#8217;s ability to shape the information landscape, particularly on Chinese social media, grows with each byte of data it gathers. This data empowers them to craft disinformation with precision, aimed at individuals based on their unique beliefs.&nbsp;
<h3 class="wp-block-heading">Fighting back</h3>
In the context of sustained US-China tensions, information warfare plays an increasingly vital role in shaping perceptions and influencing outcomes. This necessitates internet users to start scrutinizing what they see online in a much greater detail, building a new habit of scanning content for synthetic fingerprints, merging human skepticism with machine precision. At the other end of the spectrum, organizations need to step up their game in how they protect their users and customers against AI fraud. Social platforms should authenticate users, and banks must start investigating API integrations for creating additional security layers preventing KYC failures.
While Western regulators ponder changes at a snail's pace, making very little progress in the past 10 years, Chinese AI firms export tools that turbocharge disinformation in a way that makes it impossible to discern what's real, and the time to act is now.
The infodemic feeds on indifference. Without action, we'll inhabit a world where authenticity is extinct—a place where every video, voice, or contract could be a lie. The antidote? Licensing models to credit creators, detection tech to expose fakes, and ethical guardrails for AI platforms. By 2026, we'll learn whether we are able to tame this crisis—or if&nbsp; it will consume us.

Tech

China-Borne Silent Infodemic No One is Talking About

Telsey Advisory Group analyst Dana Telsey maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Outperform and raises the price target from $74 to $83.

Telsey Advisory Group Maintains Outperform on Tapestry, Raises Price Target to $83

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly gearing up to unveil five new products in March, including the iPhone SE 4, M4 MacBook Air, and a new iPad Air.
What Happened: The iPhone SE 4, Apple&#8217;s most affordable iPhone, is expected to undergo a significant upgrade, <a href="https://9to5mac.com/2025/02/02/five-apple-products-coming-soon-next-month-spring/">reported</a> 9to5Mac on Monday. The upcoming model is expected to have a design similar to the iPhone 14, incorporate an in-house modem, and include a USB-C port. It might also be rebranded as the "iPhone 16E."
Apple&#8217;s budget iPad is slated for its first update in more than two years, featuring Apple Intelligence support and the new A17 Pro chip.
SEE ALSO: <a href="https://www.benzinga.com/25/01/43294364/apple-surprises-iphone-users-by-teaming-up-with-spacex-and-t-mobile-to-bring-starlink-satellite-texting-heres-what-you-need-to-know-about-the-new-feature">Apple Surprises Users With Starlink Beta, Teams Up With Elon Musk&#8217;s SpaceX And T-Mobile To Bring Satellite Texting For iPhone Users In iOS 18.3</a>
The MacBook Air is set to receive a chip upgrade to the M4, while the iPad Air is anticipated to feature an M3 chip along with a new Magic Keyboard.
Apple&#8217;s first smart home device with a display is set to launch next month, incorporating Apple Intelligence support. Furthermore, a refreshed AirTag model featuring an upgraded ultra-wideband chipset is anticipated to be released.
Why It Matters: The new lineup of Apple products is expected to be unveiled at the company&#8217;s spring product launch event in March, as <a href="https://www.macrumors.com/guide/apple-event/">reported</a> by MacRumors. The event is anticipated to showcase a range of new devices, including the iPhone SE 4, the M4 MacBook Air, and the new iPad Air.
These new product releases are expected to have a significant impact on Apple&#8217;s performance in the market, especially considering the company&#8217;s recent <a href="https://www.business-standard.com/technology/tech-news/apple-s-2025-lineup-iphone-se-4-m4-macbook-air-and-more-expected-soon-125020300727_1.html">focus on affordability and accessibility</a>.
<ul>
<li>READ NEXT: <a href="https://www.benzinga.com/tech/25/02/43424187/apples-struggles-in-ai-and-ar-indicate-a-loss-in-product-edge">Apple&#8217;s Struggles in AI and AR Indicate a Loss in Product Edge</a></li>
</ul>
This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

AAPL

Apple's Spring 2025 Lineup: iPhone SE 4, M4 Macbook Air And More Expected Soon

Telsey Advisory Group analyst Joseph Feldman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and maintains $1100 price target.

COST

Telsey Advisory Group Maintains Outperform on Costco Wholesale, Maintains $1100 Price Target

Murata Manufacturing (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRAAY#OTC">MRAAY</a>) reported quarterly earnings of $0.25 per share. This is a 177.78 percent increase over earnings of $0.09 per share from the same period last year. The company reported $2.94 billion in sales this quarter. This is a 1.14 percent decrease over sales of $2.97 billion the same period last year.

MRAAY

Murata Manufacturing Q3 EPS $0.25 Up From $0.09 YoY, Sales $2.94B Down From $2.97B YoY

An announcement from Cingulate Inc ( ($CING) ) is now available. Cingulate Inc. has reinstated the pre-cut salaries of its top executives and conti...

Cingulate Inc: Executive Pay Restored, Funding Up, FDA Study Launched

Cingulate files to sell 1.5M shares of common stock for holders

Cingulate reports Q3 results

Maxim upgraded Cingulate (CING) to Buy from Hold with an $8 price target Published first on TheFly – the ultimate source for real-time, market-movi...

Cingulate upgraded to Buy from Hold at Maxim

Cingulate (CING) has completed a financing transaction with an accredited investor which provided net proceeds to CING of $5M. The transaction was ...

Cingulate completes financing transaction for net proceeds of $5M

The latest announcement is out from Cingulate Inc ( ($CING) ). Cingulate Inc. has secured a $5 million financing arrangement through an unsecured p...

Cingulate Inc Secures $5M Financing for Strategic Growth

Cingulate (CING) announced that it has completed its final FDA-required study, which is a food effect study, for CTx-1301 for the treatment of Atte...

Cingulate completed final FDA-required study for CTx-1301 for ADHD

Cingulate Inc ( ($CING) ) has provided an announcement. Cingulate Inc. announced the completion of its final FDA-required food effect study for CTx...

Cingulate Inc Completes Key FDA Study for ADHD Drug

Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on Cingulate Inc (CING – Research Report). The associated price target remains t...

Cingulate Inc's Promising Market Positioning and Accelerated Path to Market Entry for CTx-1301

Roth MKM initiated coverage of Cingulate (CING) with a Buy rating and $12 price target The firm's optimism is driven by CTx-1301's Phase 3 data dem...

Cingulate initiated with a Buy at Roth MKM

CING

Screenshot 2024-09-03 at 6.27.41 PM

Biotech

Interview

New ADHD Medication Is On Track For NDA Filing Within A Year – Hear From This Biotech&#39;s CEO

Screenshot 2024-07-02 at 9.57.07 AM

This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment

Screenshot 2024-06-17 at 5.44.16 PM

Cingulate (NASDAQ: CING) Receives FDA Clearance To Apply For New ADHD Drug Approval

Screenshot 2024-05-07 at 10.50.27 PM

FDA New Drug Application In The Works For This Innovator In ADHD Drug Delivery

Press Releases

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Legal

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Cingulate Announces Adjournment of Special Meeting

Cingulate to Participate in Benzinga All Live Access Event

September 04, 2024 09:00 AM, Eastern

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Health Care

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Financing

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Final Study Completed for Cingulate's Lead Asset CTx-1301

CINGW

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Athira Pharma

Aytu BioPharma

Biofrontera

Cara Therapeutics

Cocrystal Pharma

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Durect

Gelteq

Hoth Therapeutics

Impact BioMedical

IGC Pharma

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lipocine

Lyra Therapeutics

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Pulmatrix

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Relmada Therapeutics, Inc. - Common Stock

Comments

Cingulate

空売り

Cingulate (NASDAQ:CING) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル